SCHEDULE: Caligan Partners Amends Anika Therapeutics Stake
Schedule 13D Amendment
Caligan Partners LP and David Johnson updated their beneficial ownership in Anika Therapeutics, Inc., maintaining a 9.95% stake and disclosing cash-settled derivative agreements.
Summary
- Caligan Partners LP and David Johnson filed Amendment No. 4 to their Schedule 13D regarding Anika Therapeutics, Inc.
- They beneficially own 1,435,130 shares of Common Stock, representing 9.95% of the outstanding shares.
- This percentage is based on 14,421,219 shares outstanding as of October 29, 2025, as reported in Anika Therapeutics' Quarterly Report on Form 10-Q.
- No transactions in Anika Therapeutics shares were effected by the reporting persons during the past 60 days.
- Caligan Fund and Caligan Accounts have entered into cash-settled derivative agreements (swaps) referencing an aggregate of 306,076 shares of Common Stock.
- These derivative agreements provide economic exposure comparable to 2.0% of the shares but do not grant voting or dispositive power over the referenced shares, and the reporting persons disclaim beneficial ownership of these shares.
Sentiment
Score: 5
Explanation: Neutral filing, primarily a disclosure of beneficial ownership and derivative positions, with no explicit positive or negative news regarding company operations or financial performance.
Future Outlook
No forward-looking statements or guidance are provided in this filing.
Industry Context
Caligan Partners is recognized as an activist investor. Their significant stake and the use of derivative agreements in Anika Therapeutics, a company in the biotech/medical device sector, suggest an ongoing strategic interest. Such disclosures are common in industries where activist investors seek to influence corporate strategy or governance.
Related Party Transactions
- Caligan Fund and Caligan Accounts, entities related to Caligan Partners LP, have entered into cash-settled derivative agreements (swaps) referencing 306,076 shares of Anika Therapeutics Common Stock.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by an activist investor like Caligan Partners could signal potential future engagement with management, which might influence strategic direction or share value.
Key Dates
| Date | Description |
|---|---|
| 2023-08-17 | Initial Schedule 13D filing date by Caligan Partners LP and David Johnson. |
| 2025-10-29 | Date as of which 14,421,219 shares of Common Stock were outstanding, as reported in Anika Therapeutics' 10-Q. |
| 2025-11-05 | Date Anika Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the period ended September 30, 2025. |
| 2025-11-19 | Date of event which required the filing of this statement. |
| 2025-11-21 | Signature date for Caligan Partners LP and David Johnson on this Amendment No. 4. |
Keywords
Anika Therapeutics, Caligan Partners, Schedule 13D, Beneficial Ownership, Common Stock, Derivative Agreements, Swaps, Activist Investor, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.